drugset / Trial / NCT02247349
BMS-986012 in Relapsed/Refractory SCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.
Timeline
- Start
- 2014-11-14
- Primary completion
- 2022-12-21
- Completion
- 2022-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | atigotatug | Monoclonal antibody | — | Intravenous |